A joint venture between Chinese biotech company 3SBio Inc and CPE Funds is set to acquire the contract development and manufacturing (CDMO) business of Canadian biomanufacturing operator Therapure Biopharma Inc for $290 million.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
